drugset / Trial / NCT01446211

Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis

NCT01446211

Phase 3 Terminated 4 enrolled Nordic Pharma SAS
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the study is to assess the efficacy (superiority testing) of gusperimus compared to conventional treatment in patients with a relapse of Wegener Granulomatosis with or without ongoing steroids, and/or immunosuppressive therapy. Further, to evaluate the safety and quality of life of gusperimus treatment compared to standard treatment in patients with relapse of Wegener Granulomatosis receiving glucocorticoids.

Timeline

Start
2011-11
Primary completion
2012-11
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azathioprine Small molecule
Comparator Cyclophosphamide Other / unclassified Intravenous
Subject Gusperimus Small molecule
Comparator Methotrexate Small molecule